These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5008 related articles for article (PubMed ID: 1917148)

  • 1. Characterization of gangliosides in human uveal melanoma cells.
    Soulieres D; Rousseau A; Deschenes J; Tremblay M; Tardif M; Pelletier G
    Int J Cancer; 1991 Oct; 49(4):498-503. PubMed ID: 1917148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variations in the ganglioside profile of uveal melanoma correlate with cytologic heterogeneity.
    Kanda S; Cochran AJ; Lee WR; Morton DL; Irie RF
    Int J Cancer; 1992 Nov; 52(5):682-7. PubMed ID: 1428227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of anti-ganglioside antibodies on the metastatic spread of intraocular melanomas in a nude mouse model of human uveal melanoma.
    Niederkorn JY; Mellon J; Pidherney M; Mayhew E; Anand R
    Curr Eye Res; 1993 Apr; 12(4):347-58. PubMed ID: 8319494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gangliosides in human uveal melanoma metastatic process.
    Tardif M; Coulombe J; Soulières D; Rousseau AP; Pelletier G
    Int J Cancer; 1996 Sep; 68(1):97-101. PubMed ID: 8895547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gangliosides of human melanoma.
    Tsuchida T; Saxton RE; Morton DL; Irie RF
    J Natl Cancer Inst; 1987 Jan; 78(1):45-54. PubMed ID: 3467129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential roles of gangliosides in malignant properties of melanomas.
    Ohmi Y; Kambe M; Ohkawa Y; Hamamura K; Tajima O; Takeuchi R; Furukawa K; Furukawa K
    PLoS One; 2018; 13(11):e0206881. PubMed ID: 30462668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography.
    Hamilton WB; Helling F; Lloyd KO; Livingston PO
    Int J Cancer; 1993 Feb; 53(4):566-73. PubMed ID: 8436430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant expression of gangliosides in human renal cell carcinomas.
    Hoon DS; Okun E; Neuwirth H; Morton DL; Irie RF
    J Urol; 1993 Dec; 150(6):2013-8. PubMed ID: 8230555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells.
    Lloyd KO; Gordon CM; Thampoe IJ; DiBenedetto C
    Cancer Res; 1992 Sep; 52(18):4948-53. PubMed ID: 1516051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycosylation pathways in the biosynthesis of gangliosides in melanoma and neuroblastoma cells: relative glycosyltransferase levels determine ganglioside patterns.
    Ruan S; Lloyd KO
    Cancer Res; 1992 Oct; 52(20):5725-31. PubMed ID: 1394196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse.
    Livingston PO; Ritter G; Calves MJ
    Cancer Immunol Immunother; 1989; 29(3):179-84. PubMed ID: 2731184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with corresponding mouse monoclonal antibodies.
    Furukawa K; Yamaguchi H; Oettgen HF; Old LJ; Lloyd KO
    Cancer Res; 1989 Jan; 49(1):191-6. PubMed ID: 2908845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ganglioside composition and its relation to clinical data in brain tumors.
    Shinoura N; Dohi T; Kondo T; Yoshioka M; Takakura K; Oshima M
    Neurosurgery; 1992 Sep; 31(3):541-9. PubMed ID: 1407435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gangliosides of human melanoma: GM2 and tumorigenicity.
    Tsuchida T; Saxton RE; Irie RF
    J Natl Cancer Inst; 1987 Jan; 78(1):55-60. PubMed ID: 3467130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas.
    Marshall JF; Rutherford DC; Happerfield L; Hanby A; McCartney AC; Newton-Bishop J; Hart IR
    Br J Cancer; 1998 Feb; 77(4):522-9. PubMed ID: 9484806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganglioside signatures of primary and nodal metastatic melanoma cell lines from the same patient.
    Ravindranath MH; Muthugounder S; Presser N
    Melanoma Res; 2008 Feb; 18(1):47-55. PubMed ID: 18227708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of melanoma-associated gangliosides in cancer patients.
    Tai T; Cahan LD; Tsuchida T; Saxton RE; Irie RF; Morton DL
    Int J Cancer; 1985 May; 35(5):607-12. PubMed ID: 3997282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma.
    Hersey P; Jamal O; Henderson C; Zardawi I; D'Alessandro G
    Int J Cancer; 1988 Mar; 41(3):336-43. PubMed ID: 3346097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of gangliosides GM2 and GM3 with metastatic potential to lungs of mouse B16 melanoma.
    Saha S; Mohanty KC
    J Exp Clin Cancer Res; 2003 Mar; 22(1):125-34. PubMed ID: 12725332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganglioside GM3:GD3 ratio as an index for the management of melanoma.
    Ravindranath MH; Tsuchida T; Morton DL; Irie RF
    Cancer; 1991 Jun; 67(12):3029-35. PubMed ID: 2044049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 251.